Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans*
- 26 September 1999
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 66 (3), 265-274
- https://doi.org/10.1016/s0009-9236(99)70034-2
Abstract
Background and purpose A triple therapy with omeprazole, amoxicillin (INN, amoxicilline), and clarithromycin is widely used for the eradication of Helicobacter pylori. Omeprazole and clarithromycin are metabolized by CYP2C19 and CYP3A4. This study aimed to elucidate whether clarithromycin affects the metabolism of omeprazole. Methods After administration of placebo or 400 mg clarithromycin twice a day for 3 days, 20 mg omeprazole and placebo or 400 mg clarithromycin were administered to 21 healthy volunteers. Plasma concentrations of omeprazole and clarithromycin and their metabolites were determined before and 1, 2, 3, 5, 7, 10, and 24 hours after dosing. CYP2C19 genotype status was determined by a polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) method. Results Subjects were classified into three groups on the basis of PCR‐RFLP analyses for CYP2C19: homozygous extensive metabolizer group (n = 6), heterozygous extensive metabolizer group (n = 11), and poor metabolizer group (n = 4). Mean area under the plasma concentration–time curves from 0 to 24 hours (AUC) of omeprazole in the homozygous extensive metabolizer, heterozygous extensive metabolizer, and poor metabolizer groups were significantly increased by clarithromycin from 383.9 to 813.1, from 1001.9 to 2110.4, and from 5589.7 to 13098.6 ng · h/mL, respectively. There were significant differences in the mean AUC values of clarithromycin among the three groups. Conclusion Clarithromycin inhibits the metabolism of omeprazole. Drug interaction between clarithromycin and omeprazole may underlie high eradication rates achieved by triple therapy with omeprazole, amoxicillin, and clarithromycin. Clinical Pharmacology & Therapeutics (1999) 66, 265–274; doi:Keywords
This publication has 35 references indexed in Scilit:
- Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcersGastroenterology, 1995
- Drug Interactions and the Cytochrome P450 SystemClinical Pharmacokinetics, 1995
- Interethnic Differences in Omeprazole Metabolism in the Two S-Mephenytoin Hydroxylation Phenotypes Studied in Caucasians and OrientalsTherapeutic Drug Monitoring, 1994
- Results of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pyloriEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Pharmacokinetic Drug Interactions of MacrolidesClinical Pharmacokinetics, 1992
- Omeprazole in the treatment of peptic ulcers resistant to H2‐receptor antagonistAlimentary Pharmacology & Therapeutics, 1990
- Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- The Gastric H+,K+-ATPase: The Site of Action of OmeprazoleScandinavian Journal of Gastroenterology, 1989
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988
- Cancer After Exposure to MetronidazoleMayo Clinic Proceedings, 1988